Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC

NCT06841874 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma
Bronchogenic Carcinoma
Non Small Cell Carcinoma of the Lung
ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Taletrectinib

Sponsor

Nuvation Bio Inc.